Book a call

Case study · Pharma compliance software · Ireland into Europe

42 sales qualified leads for an early-stage AI platform in pharma compliance.

An early-stage AI platform for pharma compliance was up against established vendors. Buyers worried about data security, about AI replacing expert judgement, and about switching from tools they already used. So each segment got its own message.

Led by our founder · Figures from the client’s report · Name withheld

42sales qualified leadsfrom 5,500 contacts researched by hand, in 6 months
20%of LinkedIn invitations acceptedby R&D, compliance, QA and C-suite people
19%of new connections repliedto a message written for their segment
Industry
Pharma compliance software
Based in
Ireland
Markets
Europe and global pharma
Length
6 months
Channels
LinkedIn and email
Green and white capsules in a blister pack on a pale lilac surface
Capsules in a blister pack. Photo: Melany @ tuinfosalud.com, Unsplash

At a glance

Pharma compliance software · Ireland

The client and the goal

The client
An early-stage AI platform for pharma compliance in Ireland, a team of 2 to 10.
Who they sell to
R&D managers, compliance officers, quality assurance managers and C-suite at large pharma companies, smaller firms and independent consultants.
The goal at the start
Reach decision makers their own LinkedIn messages and articles were not reaching, against established vendors.
The message angle
One message per segment: faster documents and compliance for big pharma; regulatory help and process automation for smaller firms and consultants.
IrelandEurope

The market

From Ireland into European pharma.

  • Ireland: the client’s base
  • Europe: the target market

Countries shaded from the report’s target, “Europe and global pharma”; Russia and Turkey are left plain because the report does not say how far east it went. Map data: Natural Earth.

What we did

  1. Researched 5,500 contacts by hand.

    R&D, compliance, QA and C-suite contacts, each researched by hand and segmented by role and by company size.

    R&DComplianceQAC-suite
    Segmented by roleand by company size
  2. Wrote one message per segment.

    Big pharma heard about faster documents and compliance management. Smaller firms and independent consultants heard about regulatory help and process automation.

    1Big pharma: faster documents and compliance

    2Smaller firms and consultants: regulatory help

    3Refined as the replies came in

    Each group got its own message.

  3. Ran LinkedIn and email side by side.

    Both channels ran together for 6 months.

    LinkedIn
    Email
    123456

    Six months, both channels every month; the strip shows time, not results.

What the work looked like

Channel plan2 channels
  1. LinkedInside by side with email
  2. Emailside by side with LinkedIn

Results

Campaign resultsPharma compliance software · Ireland
42sales qualified leads
19%reply rate
20%LinkedIn acceptance
5,500prospects, researched by hand

Exhibit 1

About one in 131 contacts researched by hand became a qualified lead.

The campaign, stage by stage

Reached
5,500R&D, compliance, QA and C-suite contacts

20% of LinkedIn invitations

19% of connections wrote back

Qualified
42sales qualified leads

The figures leave room for the result: 5,500 people x 20% accepted x 19% replied is at most about 210 replies, and 42 became qualified leads (our arithmetic). A qualified lead is a buyer who fits the brief and agreed to talk.

See the numbers
Reached5,500
Accepted20%
Replied19%
Qualified42

Exhibit 2

Acceptance and replies both ran at about the median for LinkedIn campaigns.

This campaign against public benchmarks, %

MedianHeyReach strong rangeThis campaign

Invitations acceptedHeyReach 2026, 96,051 campaigns

20.831.820

New connections who repliedHeyReach 2026, reply to acceptance

18.128.919

Benchmarks from HeyReach, LinkedIn Outreach Benchmark Report 2026 (96,051 campaigns).

See the numbers
Invitations accepted: this campaign20%
Invitations accepted: median, HeyReach strong range20.75%, 31.78%
Replied: this campaign19%
Replied: median, HeyReach strong range18.1%, 28.89%

What slowed results

What slowed it

Buyers worried about data security, about AI replacing expert judgement, and about why they should switch from the compliance tools they already used.

What changed

Each segment got its own message: big pharma heard about faster documents and compliance, smaller firms and consultants about regulatory help. Copy was refined as replies came in.

What you can take from this

  1. Answer the AI worry early.Buyers feared AI would replace expert judgement. Say plainly where your experts stay in charge.
  2. Segment by role and by size.QA and the C-suite worry about different things, and so do small and large companies.
  3. Research and segment before you send.Their own LinkedIn messages and articles were not reaching decision makers. A researched, segmented campaign did.

Photo: Melany @ tuinfosalud.com, on Unsplash. Map: Natural Earth. Benchmarks: HeyReach 2026.

Selling into European pharma? Let’s look at it together.

A free 30-minute Outbound Review. We look at your market, your buyers and your current outreach, and say plainly whether outbound can work there.